Renaissance Technologies
RANI icon

Renaissance Technologies’s Rani Therapeutics RANI Stock Holding History

Renaissance Technologies’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$328K Buy
+430,737
New +$382K ﹤0.01% 2746
2025
Q4 		– Sell
-24,908
Closed -$12.4K – 3667
2025
Q3 		$12.4K Buy
+24,908
New +$13K ﹤0.01% 3445
2024
Q4 		– Sell
-33,199
Closed -$71.7K – 3846
2024
Q3 		$71.7K Buy
33,199
+11,499
+53% +$32.9K ﹤0.01% 3307
2024
Q2 		$82.5K Sell
21,700
-48,600
-69% -$252K ﹤0.01% 3218
2024
Q1 		$219K Buy
70,300
+26,600
+61% +$91.5K ﹤0.01% 3199
2023
Q4 		$145K Sell
43,700
-7,300
-14% -$16.9K ﹤0.01% 3220
2023
Q3 		$111K Sell
51,000
-37,201
-42% -$142K ﹤0.01% 3224
2023
Q2 		$363K Buy
88,201
+47,084
+115% +$219K ﹤0.01% 3040
2023
Q1 		$212K Buy
41,117
+2,717
+7% +$16.3K ﹤0.01% 3255
2022
Q4 		$227K Buy
+38,400
New +$280K ﹤0.01% 3363

Other funds holding RANI

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Renaissance Technologies's RANI Position: Q2 2026 in Review

Renaissance Technologies opened a new position in Rani Therapeutics (RANI) in Q2 2026: 430,737 shares worth $328K. The stake represents ﹤0.01% of the portfolio and ranks #2746 among its holdings. This is a return to the name: Renaissance Technologies previously reported a position in RANI as recently as Q3 2025.

Renaissance Technologies first reported a position in RANI in Q4 2022 and has held it in 10 quarters since. The position peaked at $363K in Q2 2023. 68 funds tracked by Wall St. Rank hold RANI as of Q2 2026.

  • Renaissance Technologies held 430,737 shares of Rani Therapeutics worth $328K as of Q2 2026.
  • Rani Therapeutics was a new Renaissance Technologies position in Q2 2026.
  • Rani Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2746 holding.
  • Renaissance Technologies first reported a position in Rani Therapeutics in Q4 2022 and has held it in 10 quarters since.
  • Renaissance Technologies's Rani Therapeutics position peaked at $363K in Q2 2023.
  • 68 funds tracked by Wall St. Rank held Rani Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.